ArticleEJIFCC2025
Association of Serum Sortilin and Insulin Resistance in Patients with Gestational Diabetes Mellitus.
Article in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gestational diabetes mellitus is a condition in which glucose intolerance develops during pregnancy. Sortilin is a type I transmembrane protein, that belongs to the VPS10 family of post-Golgi trafficking receptors that is involved in signaling, intracellular sorting, and transport of proteins. Sortilin is required for the storage of glucose and co-expressed with the glucose transporter GLUT4 in differentiated adipocytes. This study aimed to evaluate serum sortilin level in individuals with GDM and to elucidate its relation with insulin resistance. Methodology: This was a case-control study. It involved 80 pregnant women, 40 with GDM (case group) and 40 healthy pregnant women (control group). Fasting blood glucose, HbA1c, insulin, HOMA-IR, and sortilin were analyzed in all the participants. Statistical analysis was performed with SPSS, version 26.0. Results: Age, gestational week, and blood pressure showed no significant difference in both groups. Body mass Index (BMI), fasting blood glucose, glycated hemoglobin (HbA1c), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and sortilin were significantly higher in the GDM group. Maternal serum sortilin showed a statistically significant positive correlation with BMI, fasting plasma glucose, serum insulin, HOMA-IR, and HbA1c. (r:0.37, p:<0.05; r:0.64, p:<0.001; r:0.38, p:<0.001; r:0.42, p<0.001, r:0.68, p<0.001 respectively). The Receiver Operating Characteristics (ROC) curve indicated sortilin as a potential biomarker for the prediction of cases with an area under a curve of 0.98 (p-value<0.001) and for the cut-off point value of >2.6ng/ml, the sensitivity was 97.5%, specificity was 97.5%, false negative rate was 2.5% and false positive rate was 2.5%. The Youden's index was 0.95, thus indicating the diagnostic accuracy of sortilin. Conclusion: This study aimed to evaluate serum sortilin level in individuals with GDM and to elucidate its relation with insulin resistance. In this study, we observed that serum sortilin concentration was significantly higher in individuals with gestational GDM than in healthy pregnant women. Also, serum sortilin had a statistically significant positive correlation with fasting blood glucose, fasting insulin, HOMA-IR, and glycated hemoglobin. The area under the curve of ROC and the Youden's index shows the impeccable diagnostic accuracy of sortilin.
Indexed as
Identifiers
41459178PMC12743336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.